What question did this study set out to answer?

The aim is to evaluate the safety and therapeutic properties of MDNA113, a tumor-targeted anti-PD1-IL-2SK agent.

MDNA113: Tumor-Targeted Anti-PD1-IL-2SK with Enhanced Safety and Efficacy

View Full Paper

Ask AI

Bookmark

The aim is to evaluate the safety and therapeutic properties of MDNA113, a tumor-targeted anti-PD1-IL-2SK agent.
Measured receptor binding using Octet Biolayer Interferometry (BLI) platform.
Assessed IL-2R signaling and PD1/PDL1 blockade via in vitro cell reporter assays.
Conducted in vivo studies in MC38 mouse syngeneic colon tumor model.
MDNA113 shows >150-fold lower affinity for IL-2Rβ compared to non-masked anti-PD1-IL-2SK.
Significant reduction in lymphocyte expansion in mice compared to MDNA223 leading to enhanced tolerability.
MDNA113 inhibits tumor growth effectively, with efficacy linked to removal of the masking domain.

No takes yet. Share an insight, caveat, or question.

Demonstrates enhanced tumor-targeting and safety of MDNA113 in a mouse cancer model, indicating effective immunotherapy potential.

To et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark